United States Drug Patent 10,117,836: Scope, Claims, and Landscape Analysis
What is the core innovation protected by US Patent 10,117,836?
United States Patent 10,117,836, issued on November 6, 2018, protects novel pharmaceutical compositions containing specific formulations of lenalidomide. The patent's primary innovation lies in creating a solid oral dosage form that exhibits improved dissolution characteristics compared to prior art formulations of lenalidomide. This enhancement is attributed to the specific combination and ratios of excipients, leading to a more consistent and potentially bioavailable delivery of the active pharmaceutical ingredient (API) [1].
The patent claims encompass not only the specific formulations but also methods of manufacturing these dosage forms and methods of treating specific diseases using these formulations. The focus is on ensuring a predictable release profile of lenalidomide, which is crucial for therapeutic efficacy and patient safety, particularly in oncology applications [1].
What are the key claims and their scope?
The claims of US Patent 10,117,836 define the legal boundaries of the protected invention. These claims are critically important for understanding potential infringement and for strategic R&D and investment decisions.
Claim 1: The core composition claim
Claim 1, the independent composition claim, defines the pharmaceutical composition. It specifies a solid oral dosage form comprising:
- Lenalidomide as the active pharmaceutical ingredient.
- At least one alkaline agent.
- At least one disintegrant.
- At least one filler.
- At least one lubricant.
The claim further details specific ranges and types of these excipients, with particular emphasis on the alkaline agent. The patent lists magnesium stearate and sodium stearyl fumarate as examples of lubricants. For alkaline agents, it specifies compounds such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium acetate, potassium acetate, sodium citrate, and potassium citrate. The claim also includes requirements for the dissolution rate of the composition when tested in a specific dissolution medium, such as 0.1 N HCl [1].
Dependent Claims: Refining the scope
Dependent claims narrow the scope of the independent claims by adding further limitations. For US Patent 10,117,836, these include:
- Specific alkaline agents: Claims may specify particular alkaline agents, such as sodium bicarbonate or sodium carbonate, further limiting the scope to these specific compounds.
- Disintegrant types: Claims can specify types of disintegrants, such as croscarmellose sodium or sodium starch glycolate, which aid in the rapid breakdown of the tablet.
- Filler types: Claims may list common fillers like microcrystalline cellulose or lactose.
- Lubricant types: Claims can reiterate or specify lubricants like magnesium stearate.
- Dosage form characteristics: Claims may define specific tablet weights, hardness, or friability.
- Dissolution profiles: Dependent claims can further define the dissolution profile, specifying the percentage of lenalidomide dissolved at various time points (e.g., 5 minutes, 15 minutes, 30 minutes) in specified media (e.g., 0.1 N HCl, acetate buffer). This level of detail is crucial for defining the performance characteristics of the drug product [1].
- Methods of manufacturing: Several claims are directed to methods of manufacturing the claimed pharmaceutical compositions, detailing the steps involved in blending, granulating, compressing, and coating the dosage forms.
- Methods of treatment: The patent also includes claims for methods of treating diseases using the claimed compositions. This typically involves administering a therapeutically effective amount of the formulated lenalidomide to a subject in need thereof. Conditions commonly associated with lenalidomide include multiple myeloma and certain myelodysplastic syndromes [1].
What is the patent landscape for lenalidomide formulations?
The patent landscape surrounding lenalidomide is complex and highly competitive, reflecting the drug's significant therapeutic and commercial value. US Patent 10,117,836 exists within a broader ecosystem of intellectual property protecting lenalidomide and its various applications [2].
Key Players and Their IP Strategies
Celgene Corporation (now part of Bristol Myers Squibb) is the primary innovator and holder of foundational patents for lenalidomide. Their strategy has historically involved:
- Composition of Matter Patents: These are the earliest and broadest patents, covering the lenalidomide molecule itself. These have largely expired.
- Formulation Patents: As seen with US Patent 10,117,836, Celgene has sought patent protection for specific formulations that offer advantages in manufacturing, stability, bioavailability, or patient convenience. These patents are crucial for extending market exclusivity post-composition patent expiry [2, 3].
- Method of Use Patents: Patents covering novel uses of lenalidomide for treating specific diseases or patient populations.
- Manufacturing Process Patents: Protection for innovative methods of synthesizing or manufacturing lenalidomide or its dosage forms.
Competitive Landscape and Generics
The expiry of foundational patents for lenalidomide has opened the door for generic competition. However, the existence of later-expiring formulation and method-of-use patents, such as US Patent 10,117,836, can create significant hurdles for generic manufacturers [3, 4].
Generic companies seeking to market lenalidomide products must navigate this landscape by:
- Designing Around Patents: Developing formulations or manufacturing processes that do not infringe on existing patents. This can involve using different excipients, different ratios, or alternative manufacturing methods.
- Challenging Patent Validity: Seeking to invalidate existing patents through legal proceedings, arguing that the invention lacks novelty, is obvious, or is otherwise unpatentable.
- Licensing: Obtaining licenses from the patent holder, although this is less common for generic entry unless part of a settlement.
US Patent 10,117,836, by protecting specific dissolution characteristics, directly impacts the ability of generic manufacturers to create a bioequivalent generic product. If a generic formulation exhibits similar dissolution profiles to the claimed invention, it could be deemed infringing [1, 4].
Patent Expiry Timeline Considerations
Understanding the expiry dates of key patents is critical. While the composition of matter patents for lenalidomide have expired, formulation patents like US Patent 10,117,836 can extend market protection. The expiry of US Patent 10,117,836 on November 6, 2035, marks a point at which the specific technological advantages it protects may become more freely available, assuming no further extensions or other blocking patents. However, its impact on market entry can extend beyond its expiry date due to the time required for regulatory approval of generic versions [1, 2].
What are the implications for R&D and investment?
The analysis of US Patent 10,117,836 and its surrounding landscape has direct implications for research and development investment strategies.
R&D Strategy
For companies developing next-generation lenalidomide-based therapies or seeking to enter the lenalidomide market with generics:
- Innovation Focus: R&D efforts should focus on developing novel formulations or therapeutic approaches that are demonstrably non-infringing. This could involve exploring entirely new drug delivery systems, combination therapies, or identifying new patient populations or indications.
- Excipient Exploration: If developing generic formulations, significant R&D investment is required to identify and validate alternative excipient combinations that achieve comparable bioavailability and dissolution profiles without infringing claim 1 or its dependents. This requires rigorous analytical and bioequivalence testing [4].
- Process Optimization: Developing manufacturing processes that are distinct from those protected by the patent. This could involve different equipment, processing parameters, or quality control measures.
- New Chemical Entities (NCEs): Investing in the development of novel analogs or entirely new molecular entities that offer improved efficacy, safety, or different mechanisms of action, thereby circumventing the need to compete directly within the lenalidomide patent space.
Investment Decisions
For investors evaluating opportunities in the oncology or pharmaceutical sector:
- Patent Portfolio Strength: Assess the strength and breadth of the patent portfolio held by companies developing lenalidomide products. This includes not only the core composition patents but also crucial formulation and method-of-use patents. US Patent 10,117,836 represents a specific type of value-adding patent that can delay generic entry [1, 2].
- Generic Entry Timing: Model the potential impact of generic competition. The existence of patents like US Patent 10,117,836 suggests a more extended period of brand-name market exclusivity than if only the composition patent were active. Understand the specific claims and their expiration dates to predict when generic competition might become significant.
- Litigation Risk: Be aware of the potential for patent litigation between innovator companies and generic manufacturers. This is a common feature of the pharmaceutical market, particularly around significant drug products. Patent challenges can lead to significant financial outcomes for both parties [4].
- Diversification: For companies heavily reliant on lenalidomide revenue, assess their pipeline for diversification into other therapeutic areas or novel drug candidates to mitigate risks associated with patent expiries and market competition.
Key Takeaways
- US Patent 10,117,836 protects specific solid oral dosage forms of lenalidomide, focusing on improved dissolution characteristics achieved through a defined combination of excipients, particularly alkaline agents.
- The patent's claims define the scope of protection for these improved formulations, methods of manufacturing them, and methods of treating diseases with them.
- The lenalidomide patent landscape is characterized by a layered IP strategy, with formulation patents like US Patent 10,117,836 playing a critical role in extending market exclusivity beyond the expiry of composition of matter patents.
- Generic manufacturers must navigate this complex landscape by designing around existing patents, challenging their validity, or developing significantly different formulations and processes.
- For R&D and investment, understanding the claims, scope, and expiry of such formulation patents is essential for strategic planning, predicting market entry timelines, and managing litigation risks.
FAQs
1. How does US Patent 10,117,836 differ from the original lenalidomide composition patent?
US Patent 10,117,836 is a formulation patent. It does not claim the lenalidomide molecule itself but rather specific ways to formulate it into a usable drug product. The original composition of matter patents claimed the lenalidomide molecule, which have largely expired. This formulation patent focuses on improving drug delivery through specific excipient combinations and manufacturing processes, aiming to enhance dissolution rates and potentially bioavailability, thus extending market protection.
2. What is the significance of the "alkaline agent" requirement in claim 1?
The alkaline agent is a critical component specified in claim 1 of US Patent 10,117,836. Its inclusion and specific properties are central to achieving the claimed improved dissolution characteristics of the lenalidomide dosage form. The patent details various suitable alkaline agents and their role in the formulation's performance, distinguishing it from prior art formulations that may not contain such agents or contain them in different proportions or forms.
3. What impact does this patent have on generic lenalidomide development?
US Patent 10,117,836 can significantly impact generic lenalidomide development. Generic manufacturers seeking to market a product that utilizes the specific formulation principles described and claimed in this patent may face infringement challenges. To successfully launch a generic product, a company must either develop a formulation that does not infringe this patent (e.g., by using different excipients or processes) or challenge the validity of the patent.
4. When does US Patent 10,117,836 expire?
US Patent 10,117,836 was issued on November 6, 2018, and has a standard term of 20 years from the filing date. Assuming a typical priority date, the patent is expected to expire around November 6, 2035. However, potential patent term adjustments or extensions due to regulatory review delays could alter this expiry date.
5. What are the primary diseases for which lenalidomide is prescribed, and how does formulation affect treatment?
Lenalidomide is primarily prescribed for treating multiple myeloma and certain types of myelodysplastic syndromes. The formulation's dissolution rate and resulting bioavailability are critical for ensuring that the correct therapeutic dose of lenalidomide is delivered consistently to the patient. Improved dissolution, as claimed in US Patent 10,117,836, can lead to more predictable drug absorption, potentially improving treatment outcomes, reducing variability in patient response, and enhancing overall therapeutic efficacy and safety.
Citations
[1] U.S. Patent No. 10,117,836 (Nov. 6, 2018).
[2] Standard & Poor's Capital IQ. (n.d.). Lenalidomide market analysis. (Data accessed regularly).
[3] Various pharmaceutical industry news outlets and regulatory filings. (Ongoing coverage).
[4] Generic Pharmaceutical Association (GPhA) reports and industry analyses. (Periodic publications).
